This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
intensive care | 904 |
respiratory failure | 682 |
mechanical ventilation | 616 |
acute respiratory | 540 |
care unit | 472 |
critically ill | 442 |
ill patients | 310 |
invasive ventilation | 287 |
noninvasive ventilation | 281 |
septic shock | 257 |
patients admitted | 249 |
ethics regulations | 238 |
risk factors | 233 |
icu admission | 226 |
respiratory distress | 220 |
mortality rate | 181 |
critical care | 174 |
cardiac arrest | 172 |
oxygen therapy | 168 |
hospital mortality | 157 |
patients undergoing | 153 |
thoracic surgery | 151 |
two groups | 150 |
mean age | 147 |
distress syndrome | 146 |
airway pressure | 144 |
nasal cannula | 142 |
respiratory support | 139 |
care units | 137 |
observational study | 134 |
flow nasal | 132 |
retrospective study | 131 |
icu stay | 130 |
study period | 130 |
pao fio | 129 |
severe acute | 125 |
icu patients | 121 |
organ failure | 120 |
multivariate analysis | 118 |
invasive mechanical | 117 |
positive airway | 115 |
pulmonary disease | 114 |
randomized controlled | 113 |
chronic obstructive | 111 |
mechanically ventilated | 108 |
lung injury | 107 |
systematic review | 107 |
endotracheal intubation | 106 |
respiratory syndrome | 105 |
control group | 104 |
patients treated | 103 |
obstructive pulmonary | 102 |
respiratory rate | 102 |
ml kg | 98 |
factors associated | 98 |
pressure ventilation | 97 |
adult patients | 96 |
tidal volume | 95 |
hypoxemic respiratory | 95 |
prospective study | 94 |
significantly higher | 94 |
sofa score | 94 |
niv failure | 94 |
apache ii | 93 |
ventilated patients | 91 |
high risk | 91 |
university hospital | 91 |
positive pressure | 89 |
copd patients | 87 |
mg kg | 87 |
patients receiving | 86 |
patients received | 86 |
controlled trial | 85 |
prone positioning | 85 |
saps ii | 85 |
icu mortality | 84 |
ventilatory support | 83 |
among patients | 82 |
significant difference | 82 |
cohort study | 81 |
exhaled air | 81 |
day mortality | 80 |
arterial blood | 80 |
brain injury | 78 |
pressure support | 78 |
included patients | 77 |
renal replacement | 76 |
continuous positive | 75 |
clinical practice | 74 |
blood gas | 73 |
replacement therapy | 71 |
antibiotic therapy | 71 |
logistic regression | 70 |
years old | 69 |
patients hospitalized | 69 |
infl uenza | 68 |
ards patients | 67 |
median age | 66 |
associated pneumonia | 65 |
hospital stay | 64 |
noninvasive positive | 64 |
ii score | 63 |
acquired pneumonia | 63 |
univariate analysis | 63 |
clinical trial | 62 |
niv group | 62 |
independently associated | 62 |
hypercapnic respiratory | 62 |
kidney injury | 62 |
acute hypoxemic | 61 |
coronavirus disease | 61 |
emergency department | 60 |
health care | 60 |
blood pressure | 60 |
risk factor | 59 |
arterial pressure | 59 |
increased risk | 59 |
cardiac surgery | 58 |
renal failure | 58 |
acute kidney | 58 |
expiratory pressure | 58 |
patients requiring | 57 |
ng ml | 56 |
nosocomial infections | 56 |
standard oxygen | 56 |
statistical analysis | 56 |
poor outcome | 56 |
heart rate | 55 |
extubation failure | 55 |
adverse events | 55 |
international congresses | 54 |
statistically significant | 54 |
severe ards | 54 |
cardiac output | 53 |
significantly associated | 53 |
lung resection | 53 |
clinical characteristics | 53 |
high flow | 53 |
body weight | 53 |
severe sepsis | 52 |
intubation rate | 52 |
significantly lower | 52 |
high mortality | 51 |
doc id | 51 |
traumatic brain | 51 |
central venous | 51 |
cord uid | 51 |
prone position | 51 |
fio ratio | 51 |
critical illness | 51 |
face mask | 51 |
mortality rates | 50 |
prospective observational | 50 |
sex ratio | 50 |
patients without | 50 |
consecutive patients | 50 |
heart failure | 49 |
airway management | 49 |
therapeutic hypothermia | 49 |
niv use | 49 |
icu discharge | 48 |
membrane oxygenation | 48 |
pediatric intensive | 48 |
controlled trials | 48 |
higher mortality | 47 |
positive end | 47 |
extracorporeal membrane | 47 |
prognostic factors | 47 |
cardiogenic shock | 47 |
spontaneous breathing | 46 |
neurological outcome | 46 |
significant differences | 46 |
primary outcome | 46 |
one patient | 46 |
performed using | 46 |
first days | 45 |
oxygen saturation | 45 |
infection control | 45 |
tracheal intubation | 44 |
postoperative pain | 44 |
chest tube | 44 |
significant increase | 44 |
randomized clinical | 44 |
pulmonary edema | 44 |
acute lung | 43 |
elderly patients | 43 |
endotracheal tube | 43 |
flow oxygen | 43 |
patients included | 43 |
reactive protein | 43 |
long term | 42 |
two patients | 42 |
independent risk | 42 |
predictive factors | 42 |
medical icu | 41 |
present study | 41 |
year period | 41 |
blood glucose | 41 |
clinical features | 41 |
least one | 40 |
odds ratio | 40 |
icu length | 40 |
fluid responsiveness | 40 |
increased mortality | 40 |
organ dysfunction | 40 |
acute physiology | 39 |
care medicine | 39 |
blood flow | 39 |
gas exchange | 39 |
inflammatory response | 39 |
cancer patients | 39 |
healthcare workers | 39 |
randomized trial | 39 |
public health | 38 |
support ventilation | 38 |
immunocompromised patients | 38 |
pregnant women | 38 |
air dispersion | 38 |
risk patients | 37 |
failure due | 37 |
carbon dioxide | 37 |
novel coronavirus | 37 |
pulmonary complications | 37 |
severe respiratory | 37 |
hfnc group | 36 |
protective ventilation | 36 |
average age | 36 |
clinical outcomes | 36 |
atrial fibrillation | 36 |
mean arterial | 36 |
lung ventilation | 36 |
inclusion criteria | 36 |
hospitalized patients | 36 |
retrospective cohort | 36 |
study conducted | 35 |
data collection | 35 |
patients presenting | 35 |
conventional oxygen | 35 |
chest wall | 34 |
surgical patients | 34 |
hospital admission | 34 |
pilot study | 34 |
interquartile range | 34 |
study including | 34 |
patients required | 34 |
mean duration | 33 |
retrospective analysis | 33 |
undergoing thoracic | 33 |
chronic respiratory | 33 |
septic patients | 33 |
niv may | 33 |
predictive value | 33 |
partial pressure | 33 |
leading cause | 33 |
nosocomial infection | 33 |
obese patients | 32 |
hospital length | 32 |
previous studies | 32 |
severe bronchiolitis | 32 |
informed consent | 32 |
hospital discharge | 32 |
family members | 32 |
month period | 32 |
pseudomonas aeruginosa | 32 |
glasgow coma | 31 |
one hundred | 31 |
scientific studies | 31 |
virus infection | 31 |
median duration | 31 |
support scientific | 31 |
respiratory tract | 31 |
negative pressure | 31 |
regression analysis | 31 |
research support | 31 |
surgery patients | 31 |
exclusion criteria | 31 |
using niv | 31 |
medical intensive | 31 |
acute renal | 31 |
liver transplantation | 30 |
clinical course | 30 |
treatment failure | 30 |
general anesthesia | 30 |
significantly different | 30 |
study aimed | 30 |
study population | 30 |
generating procedures | 30 |
including patients | 30 |
fluid balance | 29 |
middle east | 29 |
center study | 29 |
severity scores | 29 |
age years | 29 |
intubation rates | 29 |
cardiogenic pulmonary | 29 |
significantly increased | 29 |
cardiac index | 29 |
body mass | 29 |
east respiratory | 29 |
acute exacerbation | 29 |
patients died | 29 |
several studies | 29 |
analyzed using | 28 |
care workers | 28 |
term mortality | 28 |
mass index | 28 |
study included | 28 |
clinical trials | 28 |
induced lung | 28 |
staphylococcus aureus | 28 |
confidence interval | 28 |
made available | 28 |
baseline characteristics | 28 |
blood gases | 27 |
three patients | 27 |
failure rate | 27 |
hospital cardiac | 27 |
patients aged | 27 |
respiratory system | 27 |
success rate | 27 |
median time | 27 |
commonly used | 26 |
noninvasive mechanical | 26 |
world health | 26 |
fl ow | 26 |
nasal oxygen | 26 |
inspired oxygen | 26 |
requiring mechanical | 26 |
standard deviation | 26 |
flow rate | 26 |
cirrhotic patients | 26 |
kidney disease | 26 |
multiple organ | 26 |
pulmonary embolism | 26 |
intracranial hypertension | 26 |
nipah virus | 26 |
shock patients | 25 |
stroke volume | 25 |
hypoxemic patients | 25 |
blood culture | 25 |
patient safety | 25 |
study showed | 25 |
may also | 25 |
diaphragm dysfunction | 25 |
postoperative pulmonary | 25 |
side effects | 25 |
intubated patients | 25 |
medical staff | 25 |
infectious complications | 25 |
invasive mv | 25 |
hemodynamic instability | 25 |
line therapy | 25 |
esophageal pressure | 25 |
platelet count | 25 |
acute rf | 24 |
respiratory syncytial | 24 |
clinical data | 24 |
bacterial infection | 24 |
retrospective observational | 24 |
syncytial virus | 24 |
demographic data | 24 |
niv trial | 24 |
descriptive study | 24 |
status epilepticus | 24 |
pg ml | 24 |
cannula oxygen | 24 |
collected data | 24 |
medical patients | 24 |
study design | 24 |
united states | 24 |
glucose levels | 24 |
france correspondence | 24 |
infected patients | 23 |
hfot niv | 23 |
blood cell | 23 |
international license | 23 |
brain tissue | 23 |
health organization | 23 |
severity score | 23 |
tidal volumes | 23 |
copd exacerbation | 23 |
required mechanical | 23 |
version posted | 23 |
oxygen delivery | 23 |
operating room | 23 |
per patient | 23 |
prospective cohort | 23 |
overall mortality | 23 |
control study | 23 |
copyright holder | 23 |
practice guidelines | 23 |
per day | 23 |
chest physiotherapy | 23 |
ill children | 23 |
ml min | 23 |
poor prognosis | 23 |
granted medrxiv | 23 |
monocentric study | 23 |
per year | 23 |
hoc analysis | 23 |
author funder | 23 |
statistical significance | 23 |
kg min | 23 |
patient outcomes | 23 |
secondary outcomes | 23 |
within days | 23 |
home niv | 22 |
patients presented | 22 |
acquired infections | 22 |
respiratory mechanics | 22 |
data suggest | 22 |
medical records | 22 |
patients underwent | 22 |
medical history | 22 |
assessed using | 22 |
primary endpoint | 22 |
infectious diseases | 22 |
clinical signs | 22 |
enteral nutrition | 22 |
single center | 22 |
higher risk | 22 |
teaching hospital | 22 |
sofa scores | 22 |
protective equipment | 22 |
respiratory effort | 22 |
lung cancer | 22 |
respiratory disease | 22 |
circulatory failure | 22 |
respiratory infections | 22 |
driving pressure | 22 |
six patients | 22 |
higher rate | 22 |
results suggest | 22 |
physiology score | 21 |
roc curve | 21 |
coronary artery | 21 |
plateau pressure | 21 |
postoperative complications | 21 |
coma scale | 21 |
network meta | 21 |
time points | 21 |
randomised controlled | 21 |
niv users | 21 |
vasoactive drugs | 21 |
antibiotic treatment | 21 |
burn patients | 21 |
care patients | 21 |
chronic health | 21 |
high morbidity | 21 |
blood cultures | 21 |
abdominal surgery | 21 |
neuromuscular blockade | 21 |
prospectively collected | 21 |
incidence rate | 21 |
pandemic influenza | 21 |
venous catheter | 21 |
ischemic stroke | 20 |
survival rate | 20 |
imv group | 20 |
multicenter study | 20 |
arterial oxygen | 20 |
renal function | 20 |
first episode | 20 |
mortality risk | 20 |
fair strength | 20 |
sequential organ | 20 |
receiving niv | 20 |
thoracic society | 20 |
analysis showed | 20 |
continuous variables | 20 |
identify factors | 20 |
acinetobacter baumannii | 20 |
predicted body | 20 |
non invasive | 20 |
prospective randomized | 20 |
failure assessment | 20 |
ventilator circuit | 20 |
four patients | 20 |
nosocomial transmission | 20 |
selected patients | 20 |
data analysis | 20 |
pulmonary infection | 20 |
blood samples | 20 |
beneficial effects | 19 |
fiberoptic bronchoscopy | 19 |
post hoc | 19 |
intracranial pressure | 19 |
ill adults | 19 |
simplified acute | 19 |
ventilator settings | 19 |
lung disease | 19 |
observational cohort | 19 |
personal protective | 19 |
failed niv | 19 |
patients developed | 19 |
patients may | 19 |
face masks | 19 |
significantly reduced | 19 |
neurological recovery | 19 |
eight patients | 19 |
breathing trial | 19 |
myocardial infarction | 19 |
adverse effects | 19 |
last years | 19 |
may help | 19 |
sample size | 19 |
good outcome | 19 |
patients infected | 19 |
control cohort | 19 |
parenteral nutrition | 19 |
prospective multicenter | 19 |
failure requiring | 19 |
recombinant baculoviruses | 19 |
pleural effusion | 18 |
nursing staff | 18 |
preliminary results | 18 |
chronic kidney | 18 |
prognostic value | 18 |
therapeutic management | 18 |
first pass | 18 |
study group | 18 |
severe hypoxemia | 18 |
hemodynamic parameters | 18 |
respiratory acidosis | 18 |
right ventricular | 18 |
care setting | 18 |
trauma patients | 18 |
median length | 18 |
hong kong | 18 |
fluid administration | 18 |
multivariate logistic | 18 |
first day | 18 |
niv success | 18 |
health problem | 18 |
liver failure | 18 |
negative predictive | 18 |
lumen tube | 18 |
infectious disease | 18 |
regression model | 18 |
five patients | 18 |
ethics committee | 18 |
received niv | 18 |
urine output | 17 |
acute hypercapnic | 17 |
exact test | 17 |
acute care | 17 |
severe cap | 17 |
primary objective | 17 |
exhalation port | 17 |
metabolic acidosis | 17 |
acute exacerbations | 17 |
significant reduction | 17 |
per cent | 17 |
left ventricular | 17 |
gold standard | 17 |
hypoxic respiratory | 17 |
improve oxygenation | 17 |
acute cardiogenic | 17 |
ventilation via | 17 |
time spent | 17 |
severe copd | 17 |
average length | 17 |
lung surgery | 17 |
cardiothoracic surgery | 17 |
outside icu | 17 |
health evaluation | 17 |
groups according | 17 |
vital signs | 17 |
syndrome coronavirus | 17 |
ill medical | 17 |
acute phase | 17 |
assess whether | 17 |
may result | 17 |
routine use | 17 |
demographic characteristics | 17 |
additional file | 17 |
lower respiratory | 17 |
viral infection | 17 |
organ support | 17 |
care bundle | 17 |
creatinine clearance | 17 |
previously described | 17 |
onset vap | 17 |
independent predictor | 16 |
immune response | 16 |
categorical variables | 16 |
good strength | 16 |
conventional ventilation | 16 |
team functionality | 16 |
dead space | 16 |
biological data | 16 |
extubation respiratory | 16 |
palliative care | 16 |
may lead | 16 |
niv patients | 16 |
postoperative respiratory | 16 |
respiratory illness | 16 |
determined using | 16 |
invasive positive | 16 |
unfavorable outcome | 16 |
pulmonary oedema | 16 |
disease severity | 16 |
epidural analgesia | 16 |
results patients | 16 |
shockable rhythm | 16 |
oxygen mask | 16 |
medical care | 16 |
data collected | 16 |
recent study | 16 |
pk pd | 16 |
hematologic malignancies | 16 |
hypoxemic arf | 16 |
neutralization antibody | 16 |
heart disease | 16 |
prolonged mechanical | 16 |
beneficial effect | 16 |
determine whether | 16 |
serum creatinine | 16 |
aerosol generating | 16 |
fi rst | 16 |
clinical improvement | 16 |
one case | 16 |
failure noninvasive | 16 |
clinical presentation | 16 |
negative bacilli | 16 |
weaning failure | 16 |
patient comfort | 16 |
nine patients | 16 |
risk procedure | 16 |
lung volume | 16 |
guidelines recommend | 16 |
lactate levels | 16 |
gas analysis | 16 |
diabetes mellitus | 16 |
study performed | 16 |
niv treatment | 16 |
standard care | 16 |
task force | 16 |
cardiopulmonary resuscitation | 16 |
peer review | 16 |
enhanced recovery | 16 |
tract infection | 16 |
patient care | 16 |
respiratory diseases | 16 |
measured using | 16 |
aerosol dispersion | 16 |
planned extubation | 15 |
mask ventilation | 15 |
refractory cardiac | 15 |
low tidal | 15 |
systemic inflammatory | 15 |
bed medical | 15 |
ventilation strategy | 15 |
venturi mask | 15 |
protective effect | 15 |
medical procedures | 15 |
cell count | 15 |
lactate level | 15 |
group versus | 15 |
pct levels | 15 |
chain reaction | 15 |
urinary tract | 15 |
aspiration pneumonia | 15 |
pulmonary resection | 15 |
remains controversial | 15 |
volume expansion | 15 |
hepatic encephalopathy | 15 |
hendra virus | 15 |
suggest considering | 15 |
vf vt | 15 |
enrolled patients | 15 |
posted november | 15 |
lung function | 15 |
control measures | 15 |
french icus | 15 |
life support | 15 |
community acquired | 15 |
support methods | 15 |
thoracic epidural | 15 |
mortality among | 15 |
median sofa | 15 |
significant association | 15 |
severe pneumonia | 15 |
undergoing major | 15 |
viral infections | 15 |
cranial trauma | 15 |
high level | 15 |
polymerase chain | 15 |
pass success | 15 |
helmet cpap | 15 |
surviving sepsis | 15 |
medrxiv preprint | 15 |
brain death | 15 |
gene expression | 15 |
reduce postoperative | 15 |
controlled study | 15 |
continuous infusion | 15 |
free days | 15 |
subgroup analyses | 15 |
supine position | 14 |
blood transfusion | 14 |
compared using | 14 |
bed icu | 14 |
without obesity | 14 |
year mortality | 14 |
sensitivity analysis | 14 |
bronchoalveolar lavage | 14 |
intervention group | 14 |
common cause | 14 |
niv therapy | 14 |
positive predictive | 14 |
morbidly obese | 14 |
international guidelines | 14 |
patients within | 14 |
health workers | 14 |
considered significant | 14 |
grant acknowledgment | 14 |
significant correlation | 14 |
general hospital | 14 |
main objective | 14 |
month mortality | 14 |
acute brain | 14 |
seven patients | 14 |
evaluated using | 14 |
ventilator associated | 14 |
core temperature | 14 |
american thoracic | 14 |
acinetobacter baumanii | 14 |
direct examination | 14 |
lung compliance | 14 |
surgical icu | 14 |
flow cytometry | 14 |
large droplets | 14 |
isolation room | 14 |
prognostic impact | 14 |
awake proning | 14 |
increased significantly | 14 |
average time | 14 |
severe brain | 14 |
year survival | 14 |
particle dispersion | 14 |
opioid consumption | 14 |
injury severity | 14 |
hypercapnic copd | 14 |
acute pancreatitis | 14 |
burned patients | 14 |
difficult intubation | 14 |
vasopressor support | 14 |
fluid therapy | 14 |
significant decrease | 14 |
white blood | 14 |
sepsis campaign | 14 |
acquired weakness | 14 |
clinical management | 14 |
clinical outcome | 14 |
organ failures | 14 |
severe tbi | 14 |
icu management | 14 |
rsv infection | 14 |
clinical impact | 14 |
high volume | 14 |
making process | 14 |
healthcare use | 14 |
hematological malignancies | 14 |
organ donation | 14 |
nitric oxide | 14 |
healthy subjects | 13 |
enteral feeding | 13 |
transthoracic echocardiography | 13 |
children admitted | 13 |
recruitment maneuver | 13 |
study shows | 13 |
tube removal | 13 |
signifi cant | 13 |
confirmed covid | 13 |
droplet dispersion | 13 |
underlying disease | 13 |
discharged alive | 13 |
longer duration | 13 |
acute circulatory | 13 |
even though | 13 |
independent factors | 13 |
volume ventilation | 13 |
transpulmonary thermodilution | 13 |
receiver operating | 13 |
small number | 13 |
mental status | 13 |
nasal mask | 13 |
niv non | 13 |
included trials | 13 |
weaning protocol | 13 |
without significant | 13 |
ill cancer | 13 |
paravertebral block | 13 |
cardiac arrests | 13 |
endothelial cells | 13 |
fluid challenge | 13 |
hazard ratio | 13 |
well tolerated | 13 |
acute poisoning | 13 |
experimental group | 13 |
high rate | 13 |
required invasive | 13 |
improved survival | 13 |
stem cell | 13 |
multimodal analgesia | 13 |
alveolar recruitment | 13 |
adverse event | 13 |
smoke particles | 13 |
end point | 13 |
mechanical power | 13 |
low mortality | 13 |
fluid resuscitation | 13 |
antibiotic prophylaxis | 13 |
single centre | 13 |
klebsiella pneumoniae | 13 |
national health | 13 |
dispersion distance | 13 |
ill patient | 13 |
total number | 13 |
moderate ards | 13 |
red blood | 13 |
bacterial clearance | 13 |
oral care | 13 |
diabetic ketoacidosis | 13 |
chest trauma | 13 |
multivariate regression | 13 |
serum levels | 13 |
rank test | 13 |
ahrf secondary | 13 |
defined according | 13 |
respiratory care | 12 |
surgical site | 12 |
early diagnosis | 12 |
noninvasive respiratory | 12 |
end expiratory | 12 |
case series | 12 |
full treatment | 12 |
postoperative care | 12 |
first time | 12 |
icu team | 12 |
square test | 12 |
supplemental oxygen | 12 |
sodium lactate | 12 |
hypercapnic acidosis | 12 |
recent years | 12 |
systolic function | 12 |
ten patients | 12 |
patients according | 12 |
cumulative incidence | 12 |
admitted patients | 12 |
transport team | 12 |
intermediate care | 12 |
first year | 12 |
antibiotic prescription | 12 |
decompressive craniectomy | 12 |
postoperative delirium | 12 |
respiratory muscles | 12 |
average duration | 12 |
undergoing niv | 12 |
used niv | 12 |
pulmonary function | 12 |
nervous system | 12 |
bacterial pneumonia | 12 |
differed significantly | 12 |
lower mortality | 12 |
poor strength | 12 |
computed tomography | 12 |
health insurance | 12 |
membrane fusion | 12 |
surgical mask | 12 |
airway closure | 12 |
severe disease | 12 |
major surgery | 12 |
emergency departments | 12 |
immunosuppressed patients | 12 |
preventive measures | 12 |
severe traumatic | 12 |
niv mask | 12 |
general icu | 12 |
breaths min | 12 |
transpulmonary pressure | 12 |
antibiotic susceptibility | 12 |
high dose | 12 |
first attempt | 12 |
loading dose | 12 |
mesenteric ischemia | 12 |
required intubation | 12 |
data regarding | 12 |
extended data | 12 |
lumbar puncture | 12 |
influenza patients | 12 |
daily drug | 12 |
niv delivery | 12 |
high doses | 12 |
avoid intubation | 12 |
preliminary data | 12 |
systolic dysfunction | 12 |
spontaneously breathing | 12 |
nasal prongs | 12 |
congestive heart | 12 |
macintosh laryngoscope | 12 |
sleep apnea | 12 |
neuromuscular blockers | 12 |
overall survival | 12 |
main reason | 12 |
cox model | 12 |
mass casualty | 12 |
inhibitory concentration | 12 |
predict fluid | 12 |
secondary objectives | 12 |
subgroup analysis | 12 |
european society | 12 |
emergency room | 12 |
glasgow score | 12 |
old patients | 12 |
inspiratory effort | 12 |
secondary objective | 12 |
short term | 12 |
clinically relevant | 12 |
ventilator days | 12 |
analysis using | 12 |
lung ultrasound | 12 |
bilevel positive | 12 |
base deficit | 12 |
preliminary study | 12 |
care settings | 12 |
one study | 12 |
frequently used | 12 |
main causes | 12 |
diabetic patients | 12 |
target range | 12 |
primary outcomes | 12 |
nasal high | 12 |
decision making | 12 |
may improve | 12 |
widely used | 12 |
last decade | 12 |
respiratory infection | 12 |
ct scan | 12 |
ers ats | 11 |
children aged | 11 |
identified using | 11 |
fresenius medical | 11 |
medical center | 11 |
infected pneumonia | 11 |
one third | 11 |
invasive aspergillosis | 11 |
confirmed cases | 11 |
rescue therapy | 11 |
mait cells | 11 |
higher incidence | 11 |
airfl ow | 11 |
copd exacerbations | 11 |
insect cells | 11 |
lactate dehydrogenase | 11 |
patients discharged | 11 |
affiliated hospital | 11 |
multicenter cohort | 11 |
effective treatment | 11 |
qualitative data | 11 |
chronic pulmonary | 11 |
chest drainage | 11 |
implementation strategies | 11 |
time point | 11 |
mean saps | 11 |
extracorporeal life | 11 |
bacterial infections | 11 |
oxygen debt | 11 |
minute ventilation | 11 |
respiratory droplets | 11 |
available data | 11 |
oxygen consumption | 11 |
first week | 11 |
surgical intensive | 11 |
bacterial resistance | 11 |
myocardial dysfunction | 11 |
laboratory findings | 11 |
bloodstream infections | 11 |
patients experienced | 11 |
niv hfnc | 11 |
pandemic infl | 11 |
remote monitoring | 11 |
head trauma | 11 |
new zealand | 11 |
niv initiation | 11 |
systemic inflammation | 11 |
severe hypercapnic | 11 |
first line | 11 |
nasal cpap | 11 |
evaluation ii | 11 |
patients will | 11 |
pao mmhg | 11 |
studies showed | 11 |
systematic reviews | 11 |
bnp value | 11 |
hospital admissions | 11 |
arf due | 11 |
diastolic dysfunction | 11 |
chronic renal | 11 |
organ dysfunctions | 11 |
mild therapeutic | 11 |
normal saline | 11 |
severe dyspnea | 11 |
risk infections | 11 |
mean length | 11 |
icu beds | 11 |
quantitative variables | 11 |
ibn rochd | 11 |
used hfnc | 11 |
arterial ph | 11 |
vs standard | 11 |
local signs | 11 |
confidence intervals | 11 |
clinical examination | 11 |
glyceamic control | 11 |
charlson comorbidity | 11 |
hematological malignancy | 11 |
therapeutic strategy | 11 |
received imv | 11 |
hand hygiene | 11 |
estimate rated | 11 |
score ii | 11 |
term survival | 11 |
body temperature | 11 |
breathing patients | 11 |
common complication | 11 |
patients compared | 11 |
patient outcome | 11 |
inactivated niv | 11 |
statistical difference | 11 |
influenza virus | 11 |
requiring intensive | 11 |
rt autonomy | 11 |
sagittal plane | 11 |
ventilation failure | 11 |
epidemiological characteristics | 11 |
acute pulmonary | 11 |
ohca patients | 11 |
susceptibility testing | 11 |
systolic blood | 11 |
niv application | 11 |
target temperature | 11 |
respiratory variations | 11 |
isolated bacteria | 11 |
randomly assigned | 11 |
versus conventional | 11 |
undergoing lung | 11 |
prehospital setting | 11 |
carbon monoxide | 11 |
cerebrospinal fluid | 11 |
correlation coefficient | 11 |
also significantly | 11 |
male gender | 11 |
previous study | 11 |
via different | 11 |
cannula therapy | 11 |
poor neurological | 11 |
respiratory insufficiency | 11 |
electron microscopy | 11 |
activated protein | 11 |
lst limitation | 11 |
significant improvement | 10 |
requiring intubation | 10 |
fio decreases | 10 |
acute mesenteric | 10 |
four groups | 10 |
investigate whether | 10 |
final manuscript | 10 |
fr annals | 10 |
clinical picture | 10 |
current study | 10 |
respiratory therapy | 10 |
successfully treated | 10 |
clinical settings | 10 |
died within | 10 |
med doi | 10 |
insulin therapy | 10 |
early removal | 10 |
hospital stays | 10 |
head injury | 10 |
virus fusion | 10 |
weaning process | 10 |
prospective studies | 10 |
inhaled nitric | 10 |
study patients | 10 |
springer nature | 10 |
orotracheal intubation | 10 |
poor outcomes | 10 |
clinical studies | 10 |
patients supported | 10 |
better outcome | 10 |
crit care | 10 |
patients showed | 10 |
experimental model | 10 |
related complications | 10 |
well known | 10 |
neutralizing antibody | 10 |
vibrating mesh | 10 |
significantly decreased | 10 |
diffusion method | 10 |
berlin definition | 10 |
disease patients | 10 |
patients suffering | 10 |
disease progression | 10 |
neutropenic patients | 10 |
imv cases | 10 |
emergency medicine | 10 |
operating characteristic | 10 |
lung recruitment | 10 |
institutional affiliations | 10 |
patients whose | 10 |
inflammatory responses | 10 |
general population | 10 |
inspiratory flow | 10 |
muscle membrane | 10 |
several factors | 10 |
primary end | 10 |
ab vap | 10 |
also collected | 10 |
pd target | 10 |
institutional review | 10 |
multivariable analysis | 10 |
severe hypoxemic | 10 |
functional residual | 10 |
tlr ko | 10 |
significantly improved | 10 |
independent predictors | 10 |
morbid obesity | 10 |
ecmo support | 10 |
icu ventilator | 10 |
right heart | 10 |
two studies | 10 |
published maps | 10 |
air leakage | 10 |
hospital center | 10 |
refractory cardiogenic | 10 |
whitney test | 10 |
standard therapy | 10 |
mean apache | 10 |
endobronchial intubation | 10 |
prospectively included | 10 |
tertiary care | 10 |
upper airway | 10 |
pain management | 10 |
fluid management | 10 |
postextubation respiratory | 10 |
residual capacity | 10 |
igs ii | 10 |
respiratory parameters | 10 |
patient characteristics | 10 |
adverse outcomes | 10 |
influenza pneumonia | 10 |
good neurological | 10 |
therapy alone | 10 |
normally distributed | 10 |
protocol group | 10 |
pulmonary artery | 10 |
liver disease | 10 |
ideal body | 10 |
following icu | 10 |
antimicrobial therapy | 10 |
family satisfaction | 10 |
glucose control | 10 |
obstructive sleep | 10 |
lower incidence | 10 |
delta pco | 10 |
disk diffusion | 10 |
spontaneous circulation | 10 |
remains neutral | 10 |
aki stage | 10 |
renal disease | 10 |
randomized trials | 10 |
jurisdictional claims | 10 |
plane block | 10 |
gas flow | 10 |
secondary infections | 10 |
controlled ventilation | 10 |
remaining patients | 10 |
venous catheters | 10 |
resuscitation department | 10 |
chest radiographs | 10 |
patients found | 10 |
time reverse | 10 |
excluded patients | 10 |
severe community | 10 |
major cause | 10 |
related infections | 10 |
one level | 10 |
favorable outcome | 10 |
analysis revealed | 10 |
dosing regimens | 10 |
outcome scale | 10 |
care co | 10 |
severe influenza | 10 |
com annals | 10 |
identify patients | 10 |
age group | 10 |
inspiratory pressure | 10 |
sf cells | 10 |
major thoracic | 10 |
also recorded | 10 |
nature remains | 10 |
treat acute | 10 |
higher rates | 10 |
early identification | 10 |
ventilatory assist | 10 |
gram negative | 10 |
two independent | 10 |
urinary catheter | 10 |
early use | 10 |
thirty patients | 10 |
iv infection | 10 |
multicenter randomized | 10 |
many patients | 10 |
solid tumors | 10 |
chronic af | 10 |
missing data | 10 |
supplementary material | 10 |
sedative drugs | 10 |
care society | 10 |
gas analyses | 10 |
invasive procedures | 10 |
general intensive | 10 |
groups regarding | 10 |
improves survival | 10 |
aerosol delivery | 10 |
patients using | 10 |
glasgow outcome | 10 |
abdominal surgeries | 10 |
lung safe | 9 |
twelve patients | 9 |
one patients | 9 |
patients still | 9 |
icu ventilators | 9 |
risk assessment | 9 |
purulent discharge | 9 |
group without | 9 |
feeding tube | 9 |
peripheral blood | 9 |
th day | 9 |
undergoing cardiac | 9 |
pediatric patients | 9 |
muscle weakness | 9 |
na seo | 9 |
recently published | 9 |
ventilator support | 9 |
pulmonary arterial | 9 |
study aims | 9 |
disease control | 9 |
included children | 9 |
invasive fungal | 9 |
similar results | 9 |
viral transmission | 9 |
viral pneumonia | 9 |
blood cells | 9 |
nasal masks | 9 |
cardiac rhythm | 9 |
underlying malignancy | 9 |
subarachnoid hemorrhage | 9 |
severe patients | 9 |
burn center | 9 |
total bilirubin | 9 |
hospital level | 9 |
trial comparing | 9 |
delivery via | 9 |
reduced mortality | 9 |
term outcomes | 9 |
invasively ventilated | 9 |
acute coronary | 9 |
niv intolerance | 9 |
patients needed | 9 |
rate variability | 9 |
total face | 9 |
blood loss | 9 |
thoracic surgical | 9 |
early postoperative | 9 |
main outcome | 9 |
may benefit | 9 |
practice guideline | 9 |
icu los | 9 |
linear regression | 9 |
day survival | 9 |
previously reported | 9 |
intubation procedure | 9 |
individual patient | 9 |
group compared | 9 |
complication rates | 9 |
obstructive lung | 9 |
written informed | 9 |
average hospital | 9 |
internal jugular | 9 |
early mobilization | 9 |
tbi patients | 9 |
coma score | 9 |
hemoglobin level | 9 |
resistant strains | 9 |
official ers | 9 |
months post | 9 |
see table | 9 |
maternal mortality | 9 |
results show | 9 |
respiratory society | 9 |
significant impact | 9 |
retrospectively reviewed | 9 |
steady state | 9 |
internal medicine | 9 |
rabbits immunized | 9 |
will allow | 9 |
ethical approval | 9 |
pediatric ards | 9 |
positive culture | 9 |
prospective single | 9 |
surface area | 9 |
ex vivo | 9 |
life threatening | 9 |
fungal infection | 9 |
operative complications | 9 |
initial treatment | 9 |
airborne transmission | 9 |
surgical masks | 9 |
transition period | 9 |
two different | 9 |
cell fusion | 9 |
therapeutic drug | 9 |
lymphocyte count | 9 |
infection prevention | 9 |
statistically different | 9 |
respiratory depression | 9 |
incidence density | 9 |
pulse contour | 9 |
oxygen flow | 9 |
patienten mit | 9 |
fluid loading | 9 |
aged years | 9 |
gestational age | 9 |
monoclonal antibody | 9 |
main reasons | 9 |
organ transplantation | 9 |
cerebral blood | 9 |
volatile anesthetics | 9 |
adjusted ventilatory | 9 |
defi ned | 9 |
acute onset | 9 |
therapeutic failure | 9 |
studies suggest | 9 |
delta nlr | 9 |
various respiratory | 9 |
nasogastric tube | 9 |
lung tissue | 9 |
reduce mortality | 9 |
ventilator weaning | 9 |
catheter related | 9 |
cell transplantation | 9 |
care doi | 9 |
rsv infections | 9 |
different types | 9 |
normal range | 9 |
ats clinical | 9 |
suspected infection | 9 |
continuous monitoring | 9 |
communication failures | 9 |
serum sodium | 9 |
artery bypass | 9 |
less severe | 9 |
ct scans | 9 |
respiratory symptoms | 9 |
drainage systems | 9 |
refractory hypoxemia | 9 |
drug cost | 9 |
airway pressures | 9 |
disease transmission | 9 |
first study | 9 |
propensity score | 9 |
vented mask | 9 |
showed significant | 9 |
patients diagnosed | 9 |
droplet nuclei | 9 |
jet nebulizer | 9 |
resistant bacteria | 9 |
niv cohort | 9 |
twenty patients | 9 |
aerosol generation | 9 |
chronic heart | 9 |
random effect | 9 |
least days | 9 |
hemorrhagic shock | 9 |
mainly due | 9 |
pressure rooms | 9 |
underlying diseases | 9 |
site infection | 9 |
higher peep | 9 |
statistical analyses | 9 |
drug monitoring | 9 |
may require | 9 |
innate immune | 9 |
personal protection | 9 |
median saps | 9 |
conventional mechanical | 9 |
abdominal pressure | 9 |
suspected cases | 9 |
safety culture | 9 |
preventive use | 9 |
pain scores | 9 |
training sessions | 9 |
procedure mask | 9 |
prior antibiotic | 9 |
per minute | 9 |
routine clinical | 9 |
vascular cause | 9 |
clinical variables | 9 |
still alive | 9 |
resection patients | 9 |
early sepsis | 9 |
monocentric retrospective | 9 |
much higher | 9 |
cmv reactivation | 9 |
diagnostic accuracy | 9 |
mesh nebulizer | 9 |
main cause | 9 |
renal impairment | 9 |
secondary outcome | 9 |
published data | 9 |
acute hypoxic | 9 |
patient died | 9 |
developed vap | 9 |
retrospectively studied | 9 |
appropriate treatment | 9 |
regional hospital | 9 |
electrical activity | 9 |
two cases | 9 |
chronic liver | 9 |
median delay | 9 |
therapy versus | 9 |
factors independently | 9 |
postoperative analgesia | 9 |
study suggests | 9 |
specialized advice | 9 |
important risk | 9 |
comatose patients | 9 |
fusion protein | 9 |
male predominance | 9 |
sars patients | 9 |
findings suggest | 9 |
care med | 9 |
seasonal influenza | 9 |
following cardiac | 9 |
roc curves | 9 |
frequent complication | 9 |
lymphocyte apoptosis | 9 |
niv choice | 9 |
igs score | 9 |
receiving mechanical | 9 |
neurally adjusted | 9 |
brain damage | 9 |
also associated | 9 |
three times | 9 |
patient days | 9 |
line treatment | 9 |
ivc diameter | 9 |
fi lter | 9 |
imv patients | 9 |
medical surgical | 9 |
cardiac function | 8 |
chu angers | 8 |
mixed icu | 8 |
percutaneous coronary | 8 |
glycaemic control | 8 |
ventilation treatment | 8 |
multiorgan failure | 8 |
experimental studies | 8 |
inflicted lung | 8 |
positive patients | 8 |
cardiopulmonary bypass | 8 |
home oxygen | 8 |
whisper swivel | 8 |
moderate acute | 8 |
acute liver | 8 |
patients older | 8 |
remained unchanged | 8 |
blood volume | 8 |
working group | 8 |
early recognition | 8 |
oxygen administration | 8 |
failure resulting | 8 |
renal recovery | 8 |
ko mice | 8 |
differ significantly | 8 |
hemodynamic monitoring | 8 |
response rate | 8 |
tunisia correspondence | 8 |
low flow | 8 |
unfractionated heparin | 8 |
liver cirrhosis | 8 |
escherichia coli | 8 |
mice immunized | 8 |
peep levels | 8 |
qsofa score | 8 |
oxygenation strategy | 8 |
hospital survival | 8 |
patients require | 8 |
acute stroke | 8 |
review board | 8 |
cerebral performance | 8 |
clinical information | 8 |
specifi cally | 8 |
annual congress | 8 |
remains high | 8 |
limited data | 8 |
retrospective single | 8 |
wild type | 8 |
final diagnosis | 8 |
severe covid | 8 |
initial cardiac | 8 |
critical patients | 8 |
stroke patients | 8 |
clinical situations | 8 |
early vap | 8 |
study demonstrates | 8 |
brain dead | 8 |
normalized concentration | 8 |
eye protection | 8 |
chest radiography | 8 |
ventricular fibrillation | 8 |
safe study | 8 |
inclusion period | 8 |
discharge diagnoses | 8 |
critical ill | 8 |
tube placement | 8 |
results one | 8 |
invasive respiratory | 8 |
insertion site | 8 |
ventilatory settings | 8 |
ventilation time | 8 |
better survival | 8 |
performed according | 8 |
minimum inhibitory | 8 |
sham group | 8 |
initial severity | 8 |
eligible patients | 8 |
may increase | 8 |
dispersion distances | 8 |
higher bmi | 8 |
significant morbidity | 8 |
require mechanical | 8 |
using logistic | 8 |
fisher paykel | 8 |
therapeutic intervention | 8 |
chronic diseases | 8 |
icu physicians | 8 |
associated factors | 8 |
mortality associated | 8 |
host response | 8 |
vap incidence | 8 |
retrospective descriptive | 8 |
regional anticoagulation | 8 |
increased morbidity | 8 |
life expectancy | 8 |
retrospective monocentric | 8 |
full face | 8 |
rate among | 8 |
temperature management | 8 |
associated discharge | 8 |
fab fragment | 8 |
apache score | 8 |
severe complications | 8 |
expert recommendations | 8 |
skin breakdown | 8 |
treat patients | 8 |
plateau pressures | 8 |
pulse pressure | 8 |
reintubation rate | 8 |
antimicrobial susceptibility | 8 |
casualty events | 8 |
large cohort | 8 |
esicm annual | 8 |
using univariate | 8 |
postextubation high | 8 |
phase i | 8 |
trial effect | 8 |
gastric tube | 8 |
induced pulmonary | 8 |
eeg reactivity | 8 |
clinical decision | 8 |
complications associated | 8 |
outcomes included | 8 |
sars outbreak | 8 |
clinical evaluation | 8 |
observational prospective | 8 |
arterial partial | 8 |
serious complications | 8 |
following criteria | 8 |
left ventricle | 8 |
type baculovirus | 8 |
unidentified etiology | 8 |
wall elastance | 8 |
empirical antibiotic | 8 |
qualitative study | 8 |
results showed | 8 |
per hour | 8 |
medication errors | 8 |
blood sugar | 8 |
traumatic intracranial | 8 |
team member | 8 |
performance status | 8 |
target non | 8 |
surgical procedures | 8 |
ill adult | 8 |
descriptive statistics | 8 |
factor associated | 8 |
light sheet | 8 |
early stage | 8 |
days post | 8 |
blood lactate | 8 |
capillary blood | 8 |
respiratory status | 8 |
niv cases | 8 |
niv using | 8 |
postoperative infections | 8 |
health status | 8 |
viral load | 8 |
mortality compared | 8 |
spanish society | 8 |
whole population | 8 |
hemodynamic profile | 8 |
citrate anticoagulation | 8 |
identify risk | 8 |
comfort score | 8 |
continuous intravenous | 8 |
mv weaning | 8 |
arterial lactate | 8 |
respiratory viruses | 8 |
neuromuscular blocking | 8 |
arterial hypertension | 8 |
might improve | 8 |
treatment modality | 8 |
healthy volunteers | 8 |
studies reported | 8 |
oxygen concentrator | 8 |
will use | 8 |
several limitations | 8 |
requiring invasive | 8 |
allow us | 8 |
patients reported | 8 |
central catheter | 8 |
may allow | 8 |
assisted ventilation | 8 |
immune dysfunction | 8 |
healthcare professionals | 8 |
death occurred | 8 |
center retrospective | 8 |
tertiary hospital | 8 |
solid organ | 8 |
weaning success | 8 |
developing countries | 8 |
patients ventilated | 8 |
health commission | 8 |
study day | 8 |
strong association | 8 |
line intervention | 8 |
oxygenation strategies | 8 |
hypercapnic patients | 8 |
nutritional status | 8 |
case report | 8 |
clinical research | 8 |
pneumonia caused | 8 |
study confirms | 8 |
testing laboratories | 8 |
placebo group | 8 |
authors declare | 8 |
non survivors | 8 |
icp monitoring | 8 |
high incidence | 8 |
survival time | 8 |
outcomes among | 8 |
vessel density | 8 |
function testing | 8 |
care interventions | 8 |
oxygen supplementation | 8 |
pain intensity | 8 |
posted august | 8 |
days following | 8 |
nasal cannulae | 8 |
children treated | 8 |
noninvasive continuous | 8 |
every patient | 8 |
decreased significantly | 8 |
new york | 8 |
remains unclear | 8 |
evidence suggests | 8 |
clinical study | 8 |
central nervous | 8 |
monitoring system | 8 |
failure rates | 8 |
pulmonary tuberculosis | 8 |
positive blood | 8 |
patient data | 8 |
failure caused | 8 |
infections due | 8 |
directed therapy | 8 |
ulcer prophylaxis | 8 |
neurologic outcome | 8 |
travel history | 8 |
inflammatory cytokines | 8 |
chi square | 8 |
common reason | 8 |
identified patients | 8 |
high levels | 8 |
improve patient | 8 |
days mortality | 8 |
respiratory viral | 8 |
potential risk | 8 |
bone marrow | 8 |
adverse effect | 8 |
urine samples | 8 |
hospitalized covid | 8 |
adult icu | 8 |
ventilatory strategies | 8 |
note springer | 8 |
bacterial meningitis | 8 |
leak port | 8 |
may develop | 8 |
ohca due | 8 |
rd esicm | 8 |
three different | 8 |
paediatric intensive | 8 |
drug administration | 8 |
patient without | 8 |
whole blood | 8 |
arrest related | 8 |
survivor group | 8 |
term prognosis | 8 |
involving patients | 8 |
mean bias | 8 |
advanced age | 8 |
major adverse | 8 |
factors related | 8 |
oxygen fraction | 8 |
room air | 8 |
european respiratory | 8 |
low risk | 8 |
laboratory tests | 8 |
rv failure | 8 |
dosage regimen | 8 |
baseline level | 8 |
functional status | 8 |
mild hypothermia | 8 |
also found | 8 |
stenotrophomonas maltophilia | 8 |
two hospitals | 8 |
sodium chloride | 8 |
major abdominal | 7 |
ecg method | 7 |
circulatory shock | 7 |
plasma concentration | 7 |
operation group | 7 |
respiratory secretions | 7 |
sf insect | 7 |
day one | 7 |
united kingdom | 7 |
extubated patients | 7 |
consensus conference | 7 |
neonatal outcomes | 7 |
patient selection | 7 |
serum bilirubin | 7 |
also used | 7 |
per ventilator | 7 |
first hour | 7 |
bg variability | 7 |
liquid chromatography | 7 |
weaning induced | 7 |
retrospectively collected | 7 |
anterior plane | 7 |
mm hg | 7 |
oral intake | 7 |
cannula vs | 7 |
recruitment maneuvers | 7 |
intercostal nerve | 7 |
niv failed | 7 |
diaphragmatic paralysis | 7 |
testosterone levels | 7 |
ards severity | 7 |
respiratory complications | 7 |
hospital los | 7 |
persistent aki | 7 |
traumatic stress | 7 |
prognostic factor | 7 |
log rank | 7 |
venous access | 7 |
cardiac dysfunction | 7 |
obesity paradox | 7 |
ventilator acquired | 7 |
pressure room | 7 |
ancillary study | 7 |
lung transplantation | 7 |
laboratory data | 7 |
first three | 7 |
infusion rate | 7 |
calculated using | 7 |
arrest patients | 7 |
hubei province | 7 |
pressure control | 7 |
treat respiratory | 7 |
dni patients | 7 |
receiving nmba | 7 |
initial dose | 7 |
sample collection | 7 |
expiratory muscle | 7 |
linear mixed | 7 |
mean value | 7 |
air changes | 7 |
ionized calcium | 7 |
co removal | 7 |
fluid bolus | 7 |
patient admitted | 7 |
severe cases | 7 |
respiratory rates | 7 |
randomised trial | 7 |
acute pe | 7 |
society guidelines | 7 |
icu staff | 7 |
medical conditions | 7 |
immune system | 7 |
spss software | 7 |
weaning criteria | 7 |
peep cmh | 7 |
acute cardiac | 7 |
lymphocyte ratio | 7 |
one year | 7 |
care environment | 7 |
clinical conditions | 7 |
patient self | 7 |
second part | 7 |
modified rankin | 7 |
monitoring data | 7 |
via nasal | 7 |
icu survivors | 7 |
retrospective case | 7 |
resistance profile | 7 |
disaster medicine | 7 |
using clinical | 7 |
multicenter prospective | 7 |
french intensive | 7 |
us patent | 7 |
pediatric trauma | 7 |
induced immune | 7 |
ventilator mode | 7 |
simplified score | 7 |
arf secondary | 7 |
venous catheterization | 7 |
level positive | 7 |
trial noninvasive | 7 |
mechanical ventilator | 7 |
study protocol | 7 |
transplant recipients | 7 |
immune responses | 7 |
inflammatory drugs | 7 |
erector spinae | 7 |
nasal bridge | 7 |
hydroxyethyl starch | 7 |
cuff pressure | 7 |
producing gnb | 7 |
central line | 7 |
icu acquired | 7 |
may cause | 7 |
pulmonary lobectomy | 7 |
indirect elisa | 7 |
virus infections | 7 |
data available | 7 |
diagnostic tests | 7 |
treating acute | 7 |
sitting position | 7 |
cause mortality | 7 |
fungal infections | 7 |
centre study | 7 |
lv diastolic | 7 |
cochrane systematic | 7 |
versus sham | 7 |
primary ventilatory | 7 |
study demonstrated | 7 |
survival analysis | 7 |
upper limit | 7 |
febrile respiratory | 7 |
transient aki | 7 |
literature search | 7 |
mg dl | 7 |
mean time | 7 |
thyrotropic insufficiency | 7 |
capillary perfusion | 7 |
peep level | 7 |
hemodynamic failure | 7 |
hypoxaemic respiratory | 7 |
data presented | 7 |
blood products | 7 |
refractory shock | 7 |
tissue oxygen | 7 |
frequent cause | 7 |
hospital readmission | 7 |
postoperative nausea | 7 |
advance directives | 7 |
french hospitals | 7 |
arterial line | 7 |
less likely | 7 |
performance category | 7 |
niv device | 7 |
resuscitation room | 7 |
umbilical vein | 7 |
release syndrome | 7 |
intravenous infusion | 7 |
bacterial ecology | 7 |
frozen plasma | 7 |
serious adverse | 7 |
artery disease | 7 |
patients due | 7 |
algeria correspondence | 7 |
low glucose | 7 |
reperfusion injury | 7 |
randomized study | 7 |
mean sofa | 7 |
unit patients | 7 |
air leaks | 7 |
epub ahead | 7 |
generating medical | 7 |
per group | 7 |
better patient | 7 |
healthy controls | 7 |
respiratory therapists | 7 |
adverse drug | 7 |
characteristic curve | 7 |
hypoxemic acute | 7 |
median value | 7 |
rsv patients | 7 |
emergency surgery | 7 |
severely ill | 7 |
ill cirrhotic | 7 |
strongly associated | 7 |
exhalation ports | 7 |
clinical criteria | 7 |
investigated whether | 7 |
prognosis factors | 7 |
modifiable risk | 7 |
early mortality | 7 |
significantly longer | 7 |
renal clearance | 7 |
analysis will | 7 |
prefusion conformation | 7 |
lung isolation | 7 |
nasal continuous | 7 |
may contribute | 7 |
indirect estimates | 7 |
positive control | 7 |
cells infected | 7 |
hour urine | 7 |
total duration | 7 |
venous thrombosis | 7 |
patients suffered | 7 |
studies suggested | 7 |
interval ci | 7 |
drug intoxication | 7 |
ventilation duration | 7 |
low level | 7 |
platelet counts | 7 |
attributable mortality | 7 |
death rate | 7 |
observational retrospective | 7 |
hfnc niv | 7 |
rv systolic | 7 |
large prospective | 7 |
capillary density | 7 |
days vs | 7 |
retract system | 7 |
sapsii score | 7 |
hypertonic saline | 7 |
scfv library | 7 |
consensus statement | 7 |
neurological disorders | 7 |
invasive devices | 7 |
improve survival | 7 |
cytokine release | 7 |
patient population | 7 |
spinae plane | 7 |
minimal inhibitory | 7 |
patients intubated | 7 |
expiratory positive | 7 |
serum concentrations | 7 |
training program | 7 |
variables associated | 7 |
burn intensive | 7 |
spearman correlation | 7 |
hospital death | 7 |
acute ph | 7 |
delta sofa | 7 |
study using | 7 |
note review | 7 |
clinical condition | 7 |
worse outcome | 7 |
severe trauma | 7 |
control vs | 7 |
cardiac surgical | 7 |
clavulanic acid | 7 |
severe head | 7 |
interprofessional education | 7 |
sidestream dark | 7 |
critical cases | 7 |
surgical procedure | 7 |
clinical benefits | 7 |
study clinical | 7 |
single dose | 7 |
usual care | 7 |
may impact | 7 |
quality control | 7 |
deep sedation | 7 |
common practice | 7 |
included studies | 7 |
hemorrhagic stroke | 7 |
significant risk | 7 |
computerized tomography | 7 |
undergoing vats | 7 |
bronchial blockers | 7 |
different respiratory | 7 |
difficult airway | 7 |
limb circuit | 7 |
received antibiotics | 7 |
care professionals | 7 |
diagnostic criteria | 7 |
care services | 7 |
independent variables | 7 |
effective communication | 7 |
mortality benefit | 7 |
maternal death | 7 |
noncardiac surgery | 7 |
flexible bronchoscopy | 7 |
standard deviations | 7 |
acute cdi | 7 |
late vap | 7 |
comorbidity index | 7 |
cox regression | 7 |
medical treatment | 7 |
may reduce | 7 |
antimicrobial resistance | 7 |
limited number | 7 |
expiratory port | 7 |
severe pediatric | 7 |
inlet cannula | 7 |
measles virus | 7 |
higher levels | 7 |
respiratory assistance | 7 |
ecls implantation | 7 |
serum pct | 7 |
introduction acute | 7 |
hospital wards | 7 |
study groups | 7 |
prefusion niv | 7 |
scheduled extubation | 7 |
using spss | 7 |
lombardy region | 7 |
secondary analysis | 7 |
troponin i | 7 |
observational studies | 7 |
three groups | 7 |
identifying patients | 7 |
different time | 7 |
strongly correlated | 7 |
french university | 7 |
narrative review | 7 |
identifi ed | 7 |
competing interests | 7 |
chart review | 7 |
clinical cure | 7 |
continuous renal | 7 |
severe infections | 7 |
severe infection | 7 |
undergoing elective | 7 |
lumen tubes | 7 |
older age | 7 |
small sample | 7 |
ml cmh | 7 |
events doi | 7 |
miserable outcome | 7 |
jet plume | 7 |
target cells | 7 |
nosocomial pneumonia | 7 |
hospital anxiety | 7 |
intracranial hemorrhage | 7 |
postoperative period | 7 |
clinical pulmonary | 7 |
niv noninvasive | 7 |
data obtained | 7 |
organizational readiness | 7 |
mean icu | 7 |
chest tubes | 7 |
western blot | 7 |
routinely used | 7 |
epidemiological data | 7 |
recombinant baculovirus | 7 |
triggering assay | 7 |
drug overdose | 7 |
psychological consult | 7 |
serratus anterior | 7 |
dependent lung | 7 |
functional outcome | 7 |
perfused vessel | 7 |
recombinant partial | 7 |
gas infection | 7 |
help clinicians | 7 |
median sagittal | 7 |
nerve blockade | 7 |
main etiologies | 7 |
ckd lps | 7 |
healthcare usage | 7 |
rate increased | 7 |
care system | 7 |
retrospective review | 7 |
baumannii vap | 7 |
rbc transfusion | 7 |
xa activity | 7 |
alveolar ventilation | 7 |
mean number | 7 |
nutritional support | 7 |
blocking agents | 7 |
potential therapeutic | 7 |
methods retrospective | 7 |
bacterial co | 7 |
infection score | 7 |
musical intervention | 7 |
took place | 7 |
markedly increased | 7 |
medical condition | 7 |
factors influencing | 7 |
bronchial blocker | 7 |
assisted thoracoscopic | 7 |
novel influenza | 7 |
evaluate whether | 7 |
among niv | 7 |
respiratory management | 7 |
scoring system | 7 |
intracavitary ecg | 7 |
chest pain | 7 |
gnb infection | 7 |
attachment glycoprotein | 7 |
tris ph | 7 |
patients following | 7 |
care department | 7 |
based approach | 7 |
failure complicating | 7 |
care protocol | 7 |
endothelial dysfunction | 7 |
partial niv | 7 |
table shows | 7 |
sepsis admitted | 7 |
high success | 7 |
significantly shorter | 7 |
oxygenation parameters | 7 |
study comparing | 7 |
sublingual microcirculation | 7 |
opportunistic infections | 7 |
studied patients | 7 |
macrophage recruitment | 7 |
undergoing thoracotomy | 7 |
outcome measures | 7 |
related adverse | 6 |
severe complication | 6 |
significance level | 6 |
clinically significant | 6 |
improvement program | 6 |
venous blood | 6 |
successful niv | 6 |
therapeutic options | 6 |
time course | 6 |
tested positive | 6 |
main risk | 6 |
symptomatic treatment | 6 |
major public | 6 |
vt set | 6 |
year old | 6 |
median number | 6 |
patients characteristics | 6 |
specific antibodies | 6 |
rankin scale | 6 |
convulsive status | 6 |
forty patients | 6 |
ventilation delivered | 6 |
oxidation rate | 6 |
older adults | 6 |
intravenous administration | 6 |
icu hospitalization | 6 |
facial mask | 6 |
increasingly used | 6 |
authors found | 6 |
moderate hypokalemia | 6 |
salbutamol nebulization | 6 |
inhibitory concentrations | 6 |
stress ulcer | 6 |
multimodal analgesic | 6 |
considered statistically | 6 |
confounding factors | 6 |
decision support | 6 |
operative period | 6 |
vulnerable patients | 6 |
improving global | 6 |
pressure transducer | 6 |
live niv | 6 |
high performance | 6 |
envelope protein | 6 |
recommend using | 6 |
ddd dh | 6 |
physiological effects | 6 |
specialized journals | 6 |
breathing system | 6 |
work load | 6 |
medical therapy | 6 |
lymphopenic patients | 6 |
analyses showed | 6 |
contour analysis | 6 |
serum vancomycin | 6 |
significant reductions | 6 |
deceased patients | 6 |
saps score | 6 |
min group | 6 |
may occur | 6 |
clinical scenarios | 6 |
using non | 6 |
vast majority | 6 |
prevention program | 6 |
new device | 6 |
performance liquid | 6 |
niv vs | 6 |
ionized calcemia | 6 |
patient cohort | 6 |
cpap duration | 6 |
analgesic efficacy | 6 |
appropriate ppe | 6 |
significant effect | 6 |
associated infections | 6 |
cell lymphoma | 6 |
analytical study | 6 |
consensus guidelines | 6 |
fluid overload | 6 |
ventilation vs | 6 |
young age | 6 |
french icu | 6 |
niv team | 6 |
ards group | 6 |
control patients | 6 |
aki patients | 6 |
use niv | 6 |
important factor | 6 |
accelerate pheno | 6 |
ineffective triggering | 6 |
definite probable | 6 |
icu health | 6 |
kg predicted | 6 |
diaphragm thickness | 6 |
among critically | 6 |
hemodynamic support | 6 |
severe forms | 6 |
ali ards | 6 |
mean total | 6 |
ventilatory strategy | 6 |
results indicate | 6 |
coronavirus infection | 6 |
aki group | 6 |
epidemiological profile | 6 |
predictive values | 6 |
better tolerated | 6 |
care team | 6 |
antimicrobial treatment | 6 |
uenza virus | 6 |
set vt | 6 |
pain relief | 6 |
first affiliated | 6 |
relative risk | 6 |
cd cd | 6 |
therapeutic goal | 6 |
group received | 6 |
multicenter observational | 6 |
assisted thoracic | 6 |
shock requiring | 6 |
assess air | 6 |
physiological parameters | 6 |
shorter length | 6 |
tcz administration | 6 |
educational strategies | 6 |
worse outcomes | 6 |
median icu | 6 |
healthcare team | 6 |
niv circuit | 6 |
qualitative variables | 6 |
average stay | 6 |
case reports | 6 |
collected demographic | 6 |
ectodomain trimer | 6 |
china clinical | 6 |
second line | 6 |
respiratory frequency | 6 |
among pregnant | 6 |
also showed | 6 |
cmv group | 6 |
right ventricle | 6 |
icu survival | 6 |
human monoclonal | 6 |
icu healthcare | 6 |
male patients | 6 |
impedance tomography | 6 |
caring relationship | 6 |
heated humidifi | 6 |
interquartile ranges | 6 |
viral bronchiolitis | 6 |
plasma levels | 6 |
onset af | 6 |
invasive strategy | 6 |
artificial ventilation | 6 |
implementing change | 6 |
american society | 6 |
ei group | 6 |
prognosis factor | 6 |
pulmonary infiltrates | 6 |
old admitted | 6 |
patient populations | 6 |
resistant staphylococcus | 6 |
good prognosis | 6 |
viral entry | 6 |
distributed data | 6 |
postoperative mortality | 6 |
period patients | 6 |
surgical resuscitation | 6 |
polymicrobial sepsis | 6 |
day post | 6 |
reported using | 6 |
va ecmo | 6 |
greater risk | 6 |
western blotting | 6 |
following admission | 6 |
studies show | 6 |
droplet size | 6 |
lower rates | 6 |
blood transfusions | 6 |
clinical review | 6 |
surgical avr | 6 |
protein agarose | 6 |
emergency laparotomy | 6 |
severity factors | 6 |
strict infection | 6 |
based care | 6 |
sapiens tls | 6 |
pleural pressure | 6 |
using noninvasive | 6 |
vegetative state | 6 |
median iqr | 6 |
electronic medical | 6 |
lps group | 6 |
global mortality | 6 |
ventilation mode | 6 |
multimodal approach | 6 |
life care | 6 |
using serum | 6 |
filter ionized | 6 |
last decades | 6 |
recipients admitted | 6 |
frequency oscillatory | 6 |
early treatment | 6 |
fisher exact | 6 |
months period | 6 |
premature infants | 6 |
systolic arterial | 6 |
prophylactic use | 6 |
protective measures | 6 |
fob application | 6 |
patient ratio | 6 |
respiratory therapist | 6 |
lung model | 6 |
exhaled gas | 6 |
patient received | 6 |
volume status | 6 |
daily basis | 6 |
increase mortality | 6 |
coexisting medical | 6 |
repeated measures | 6 |
volume variation | 6 |
three days | 6 |
care support | 6 |
airway care | 6 |
falciparum malaria | 6 |
mdr bacteria | 6 |
results highlight | 6 |
lower intubation | 6 |
immune cells | 6 |
ventilator care | 6 |
sensitivity analyses | 6 |
body core | 6 |
confirmed diagnosis | 6 |
will help | 6 |
biological parameters | 6 |
systolic bp | 6 |
postoperative morbidity | 6 |
severe aki | 6 |
thyroid storm | 6 |
trial high | 6 |
apnea syndrome | 6 |
venous pressure | 6 |
selected cases | 6 |
study involving | 6 |
invasive ventilatory | 6 |
among non | 6 |
received invasive | 6 |
lung protective | 6 |
pp session | 6 |
pain assessment | 6 |
flow therapy | 6 |
intubation procedures | 6 |
neutrophil count | 6 |
lg kg | 6 |
immune suppression | 6 |
fatal poisoning | 6 |
neurological status | 6 |
effi ciency | 6 |
dzp bup | 6 |
gradually increased | 6 |
increasing use | 6 |
sessions performed | 6 |
two levels | 6 |
epinephrine group | 6 |
describe clinical | 6 |
results among | 6 |
early phase | 6 |
multivariable logistic | 6 |
standard medical | 6 |
ventilation may | 6 |
membrane thrombosis | 6 |
cell counts | 6 |
initial niv | 6 |
finger pad | 6 |
death among | 6 |
trend toward | 6 |
key role | 6 |
ic patients | 6 |
ventilation support | 6 |
reverse transcription | 6 |
niv weaning | 6 |
high number | 6 |
perioperative care | 6 |
hospitals will | 6 |
spontaneous ventilation | 6 |
available resources | 6 |
mortality related | 6 |
coexisting chronic | 6 |
arterial carbon | 6 |
received either | 6 |
also demonstrated | 6 |
norepinephrine group | 6 |
thirteen patients | 6 |
illness severity | 6 |
coronary angiography | 6 |
excitable muscle | 6 |
moderate hypercapnic | 6 |
oral nutrition | 6 |
patient respiratory | 6 |
clinical deterioration | 6 |
improved oxygenation | 6 |
chronic lung | 6 |
patients enrolled | 6 |
respironics face | 6 |
operative respiratory | 6 |
antiviral therapy | 6 |
avoided intubation | 6 |
trials group | 6 |
remains unknown | 6 |
multicentre randomised | 6 |
transport ventilator | 6 |
resistance index | 6 |
second period | 6 |
retrospective nature | 6 |
laser light | 6 |
major risk | 6 |
national institute | 6 |
severe obesity | 6 |
niv percentage | 6 |
increased use | 6 |
induced hypertension | 6 |
multivariable analyses | 6 |
group patients | 6 |
plasma exchange | 6 |
leg raising | 6 |
years period | 6 |
conscious patients | 6 |
femoral site | 6 |
different respironics | 6 |
commercially available | 6 |
center effect | 6 |
received mechanical | 6 |
pressure monitoring | 6 |
evidence supporting | 6 |
influenza infection | 6 |
nebulizer treatment | 6 |
post icu | 6 |
group vs | 6 |
viral particles | 6 |
sepsis induced | 6 |
classified according | 6 |
finger cuff | 6 |